Chemotherapy Alters Childhood Cancer Mutation Profiles at Relapse

Chemotherapy, particularly platinum-based treatments, demonstrably alters mutation profiles in childhood cancers at the point of relapse, according to research published online in Nature on July 22, 2026. The study found that prior chemotherapy exposure triples the number of private mutational signatures and doubles the overall mutation burden in relapsed tumors. This indicates a substantial impact of therapy-induced tumor evolution on the genetic landscape of these cancers.

The findings highlight the critical role of treatment history in shaping the mutational characteristics of childhood cancers. The observed increase in mutation burden and the emergence of specific mutational signatures are directly linked to the genotoxic effects of chemotherapy agents. This understanding is crucial for interpreting the genomic data of relapsed tumors and for developing more targeted and effective therapeutic strategies.

Furthermore, the research suggests that these therapy-induced changes present opportunities for developing safer, de-escalated treatment approaches. By understanding the specific mutational patterns that arise as a consequence of prior treatment, clinicians may be able to tailor future therapies to be more precise, potentially reducing the long-term side effects associated with aggressive chemotherapy regimens. The study underscores the dynamic nature of cancer genomes under therapeutic pressure.